Vehicle ointment

DRUG16 trials

Sponsors

Serentis Ltd., LEO Pharma, Novartis Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc., Dermavant Sciences GmbH

Conditions

Atopic DermatitisAtopic Dermatitis (AD)Epidermal Growth FactorErythemato-telangiectatic RosaceaHand-Foot Skin Reaction (HFSR)HyperpigmentationKeratosis, ActinicNd-yttrium Aluminum Garnet Laser

Phase 1

A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris

CompletedNCT01297166

LEO PharmaPsoriasis Vulgaris

Start: 2011-02-28End: 2011-04-30Updated: 2025-02-24

A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis

CompletedNCT03004846

GlaxoSmithKlinePsoriasis

Start: 2017-02-13End: 2017-05-05Updated: 2019-04-18

MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis

CompletedNCT07182864

Minghui Pharmaceutical (Hangzhou) LtdAtopic Dermatitis (AD)

Start: 2022-01-06End: 2022-10-08Updated: 2025-09-19

Phase 2

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

CompletedNCT00882245

Serentis Ltd.Atopic Dermatitis

Start: 2009-04-30End: 2009-10-31Updated: 2009-10-30

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

CompletedNCT01449591

Novartis PharmaceuticalsErythemato-telangiectatic Rosacea

Start: 2011-09-30End: 2012-02-29Updated: 2021-02-21

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

CompletedNCT02068352

Otsuka Pharmaceutical Development & Commercialization, Inc.Atopic Dermatitis

Start: 2014-06-20End: 2015-02-03Updated: 2021-11-23

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

CompletedNCT02950922

Dermavant Sciences GmbHAtopic Dermatitis

Start: 2016-11-30End: 2017-07-03Updated: 2018-08-06

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

CompletedNCT03394677

Dermavant Sciences GmbHAtopic Dermatitis

Start: 2018-01-25End: 2018-07-02Updated: 2018-07-19

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

OnQuality Pharmaceuticals (USA) LLCHand-Foot Skin Reaction (HFSR)

Start: 2019-12-09End: 2024-06-30Target: 170Updated: 2024-03-04

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

CompletedNCT04091087

PfizerStasis Dermatitis

Start: 2020-06-26End: 2021-10-19Updated: 2022-05-02

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

CompletedNCT04664153

PfizerAtopic Dermatitis, Plaque Psoriasis

Start: 2020-12-21End: 2021-08-18Updated: 2022-08-26

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

CompletedNCT05375955

PfizerAtopic Dermatitis, Plaque Psoriasis

Start: 2022-09-26End: 2023-07-31Updated: 2024-10-02

Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo

Active, not recruitingNCT07181187

Minghui Pharmaceutical (Hangzhou) LtdVitiligo

Start: 2024-03-26End: 2026-05-14Updated: 2025-09-18

Phase 3

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

CompletedNCT06135415

Almirall, S.A.Keratosis, Actinic

Start: 2023-12-21End: 2025-11-25Updated: 2026-03-25

A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis

CompletedNCT07185282

Minghui Pharmaceutical (Hangzhou) LtdAtopic Dermatitis (AD)

Start: 2023-06-10End: 2025-08-15Updated: 2025-09-22

Unknown Phase

Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines

CompletedNCT04704245

Hallym University Kangnam Sacred Heart HospitalEpidermal Growth Factor, Hyperpigmentation, Nd-yttrium Aluminum Garnet Laser +1

Start: 2017-07-20End: 2018-12-26Updated: 2021-01-11

Related Papers

Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.

2024-02-0811 citations

Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis

JAMA Dermatology2023-12-2014 citations

NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer.

Journal of Clinical Oncology2023-02-20

Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.

Journal of Clinical Oncology2022-02-161 citations

A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients.

Journal of Clinical Oncology2021-05-20

A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy

Medicina2021-02-1318 citations

The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study.

2010-09-0713 citations